Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel

Authors

Han-Shen Tae, University of Wollongong
Marcelo O Ortells, Universidad de Morón
Arsalan Yousuf, University of Wollongong
Sophia Q Xu, Washington University School of Medicine in St. Louis
Gustav Akk, Washington University School of Medicine in St. Louis
David J Adams, University of Wollongong
Hugo R Arias, Oklahoma State University

Journal

Biochemical Pharmacology

Publication Date

5-1-2024

Volume

223

First Page

116183

Document Type

Open Access Publication

DOI

10.1016/j.bcp.2024.116183

Rights and Permissions

Tae HS, Ortells MO, Yousuf A, Xu SQ, Akk G, Adams DJ, Arias HR. Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel. Biochem Pharmacol. 2024 May;223:116183. doi: 10.1016/j.bcp.2024.116183. © 2024 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Recommended Citation

Tae, Han-Shen; Ortells, Marcelo O; Yousuf, Arsalan; Xu, Sophia Q; Akk, Gustav; Adams, David J; and Arias, Hugo R, "Tabernanthalog and ibogainalog inhibit the α7 and α9α10 nicotinic acetylcholine receptors via different mechanisms and with higher potency than the GABAA receptor and CaV2.2 channel." Biochemical Pharmacology. 223, 116183 (2024).
https://digitalcommons.wustl.edu/oa_4/4684